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Abstract
Background: Vitamin D deficiency has been associated with an increased risk of gestational diabetes mellitus 
(GDM), one of the most common pregnancy complications. The vitamin D status has never previously been 
studied in pregnant women in Iceland.
Objective: The aim of this research study was to evaluate the vitamin D status of an Icelandic cohort of preg-
nant women and the association between the vitamin D status and the GDM incidence. 
Design: Subjects included pregnant women (n = 938) who attended their first ultrasound appointment, during 
gestational weeks 11–14, between October 2017 and March 2018. The use of supplements containing vitamin 
D over the previous 3 months, height, pre-pregnancy weight, and social status were assessed using a question-
naire, and blood samples were drawn for analyzing the serum 25-hydroxyvitamin D (25OHD) concentration. 
Information regarding the incidence of GDM later in pregnancy was collected from medical records.
Results: The mean ± standard deviation of the serum 25OHD (S-25OHD) concentration in this cohort was 
63±24 nmol/L. The proportion of women with an S-25OHD concentration of ≥ 50 nmol/L (which is consid-
ered adequate) was 70%, whereas 25% had concentrations between 30 and 49.9 nmol/L (insufficient) and 5% 
had concentrations < 30 nmol/L (deficient). The majority of women (n = 766, 82%) used supplements con-
taining vitamin D on a daily basis. A gradual decrease in the proportion of women diagnosed with GDM was 
reported with increasing S-25OHD concentrations, going from 17.8% in the group with S-25OHD concentra-
tions < 30 nmol/L to 12.8% in the group with S-25OHD concentrations ≥75 nmol/L; however, the association 
was not significant (P for trend = 0.11).
Conclusion: Approximately one-third of this cohort had S-25OHD concentrations below adequate levels 
(< 50 nmol/L) during the first trimester of pregnancy, which may suggest that necessary action must be taken 
to increase their vitamin D levels. No clear association was observed between the vitamin D status and GDM 
in this study.
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Popular scientific summary
•  Vitamin D supplementation is encouraged by the Icelandic authorities and was quite widespread 
(80%) in the population studied.
•  Approximately one-third of this cohort reported S-25OHD concentrations below adequate levels 
(< 50 nmol/L) during the first trimester of pregnancy.
•  No clear association was seen between vitamin D status and GDM in the population studied.
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Vitamin D deficiency or insufficiency during preg-nancy is believed to be a common problem re-ported worldwide (1). However, the vitamin D 
status of pregnant women has never been studied in Ice-
land. In countries that receive limited sunshine, such as 
Iceland, vitamin D formation in the skin can be very lim-
ited, especially during the winter months (from October 
to March) (2, 3). A very few natural sources of vitamin D 
exist, and all Icelanders are, therefore, encouraged to con-
sume vitamin D in the form of supplements or cod liver 
oil, especially during the winter season (4).
Although the most well-established role of vitamin D 
involves the control of blood calcium concentrations and 
the maintenance of healthy bones (5), vitamin D defi-
ciency has also been associated with several other condi-
tions and diseases, including gestational diabetes mellitus 
(GDM) (1, 6). The mechanisms that underlie this asso-
ciation are not fully understood and are thought to be 
manifold (7). Vitamin D receptors are expressed by many 
different cells, including muscle cells and pancreatic beta 
cells (8), and may influence glucose metabolism, insulin 
secretion, and insulin resistance (9, 10). Studies that have 
investigated the association between the vitamin D sta-
tus and the increased gestational diabetes risk have been 
somewhat conflicting, with some studies showing that vi-
tamin D is associated with an increased risk of GDM, 
and others reporting no relationship between these two 
factors (11).
The primary aim of this study was to assess the vitamin 
D status of pregnant women in Iceland and to determine 
whether the intake of dietary supplements containing 
vitamin D was associated with 25-hydroxyvitamin D 
(25OHD) concentrations in the serum. The secondary 
aim of this study was to investigate the association be-




All women who visited the Prenatal Diagnostic Unit at 
Landspitali National University Hospital, Reykjavik, 
Iceland during gestational weeks 11–14, between 2 Oc-
tober 2017 and 28 March 2018, were invited to partici-
pate in this study. During the study period (6 months), 
1,684 women were scheduled to undergo their first ultra-
sound screening at Landspitali, corresponding to approx-
imately 77% of the total pregnant population in Iceland. 
Of these 1,684 women, 244 women (15%) were excluded 
from the study because they did not speak Icelandic and 
could, therefore, not respond to the questionnaire. Other 
exclusion criteria included women outside of  the ges-
tational weeks 11–14 defined in this study, women who 
failed to appear at their scheduled appointment times, 
and women who experienced miscarriage, which resulted 
in the  exclusion of  an additional 90 women. Of the re-
maining 1,350 women deemed to be eligible for participa-
tion, 329 declined to participate for various reasons. Of 
the 1,015 women who were enrolled in this study, blood 
samples were obtained from 942 women. Information re-
garding GDM diagnosis later in pregnancy was retrieved 
from the medical records of  837 women who also had 
their blood drawn for the assessment of  vitamin D status. 
The study was approved by the National Bioethics Com-
mittee and the Medical Directorate of  Landspitali Uni-
versity Hospital. Written informed consent was obtained 
from all participants. 
Assessment of vitamin D status
Blood samples were obtained from subjects during ges-
tational weeks 11–14. Serum samples were stored at 
−80°C until analysis of serum 25OHD (S-25OHD) 
concentration using an electrochemiluminescence im-
munoassay at the Clinical Core Laboratory, Landspitali 
University Hospital, which was performed during spring 
2019. Control samples, which are measured daily by the 
laboratory, have shown that the CV% of this analysis 
method is  approximately 4–5%. S-25OHD concentrations 
≥ 50 nmol/L were considered adequate, 30–49.9 nmol/L 
were considered insufficient, and < 30 nmol/L was defined 
as deficient (2, 5). We also report the number and rate of 
women with S-25OHD concentrations ≥ 75 nmol/L, as no 
consensus exists regarding optimal S-25OHD levels, and 
some researchers use a cut-off  value of 75 nmol/L as an 
indicator of adequate vitamin D status (12, 13).
Dietary and supplement intake and background variables
Women who agreed to participate in this study answered 
a questionnaire presented in an electronic format. The 
questionnaire included questions regarding background 
information, including maternal age, education, smoking 
habits, parity, nausea in pregnancy, pre-pregnancy weight, 
and height. Information regarding weight and height was 
used to calculate the pre-pregnancy body mass index 
(BMI, in kg/m2). BMI < 18.5 kg/m2 was defined as under-
weight, 18.5–24.9 kg/m2 as normal weight, 25–29.9 kg/m2 
as overweight, and ≥ 30.0 kg/m2 as obese.
Supplement intake during the previous 3 months 
( starting at approximately the onset of pregnancy) was 
assessed by a short food frequency questionnaire (FFQ), 
which included questions regarding the frequency of cod 
liver oil (a traditional source of vitamin D in Iceland), 
 vitamin  D supplement, and multivitamin consumption. 
Information regarding the consumption of other po-
tential dietary sources of vitamin D, such as vitamin D- 
enriched milk and oily fish, was also assessed through the 
FFQ. The development of the FFQ has previously been 
described in detail (14–16). 
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GDM
Information regarding the occurrence of  GDM was re-
trieved from maternal hospital records (ICD-10 codes 
O24.4 and O24.9, but O24.9 is used at Landspitali GDM 
treated with medications). The criteria for GDM diag-
noses were based on the recommendations of  the 2010 
International Association of  Diabetes and Pregnancy 
Study Groups (IADPSG) Consensus Panel (17). Other 
information gathered from medical records included 
gestational age, family history of  diabetes mellitus, and 
measured weight at the first and last maternal care visits, 
and were used to calculate the total weight gain during 
pregnancy.
Statistical analysis
Data from the dietary questionnaire and maternal hos-
pital records were entered in SPSS (IBM SPSS Statistics, 
version 26), where all statistical analysis was conducted. 
Data are expressed as mean ± standard deviation (SD) for 
normally distributed variables and as the median and inter-
quartile range (IQR) for skewed variables.  Dichotomous 
variables are reported as frequencies and percentages (%). 
For continuous variables, an independent sample T-test 
was used to formally test the significance of differences 
between the two groups of normally distributed variables, 
and the Mann-Whitney U test was used to assess the dif-
ferences among skewed variables. The Chi-square test was 
used to test differences in dichotomous variables across 
groups. 
Logistic regression analysis was used to examine as-
sociations between categories of S-25OHD status (< 30, 
30–49.9, 50–74.9, and ≥ 75 nmol/L) and GDM occur-
rence. The results are presented as odds ratios (ORs) with 
95% confidence intervals (95% CIs), both before and after 
adjustment for covariates, using the deficient S-25OHD 
status (< 30 nmol/L) as the reference category. The co-
variates included in our adjusted models were maternal 
age, pre-pregnancy BMI, parity, and smoking during 
pregnancy. As a formal test for an association, we used 
the Chi-square test by modeling categorical variables as 
continuous terms in the regression model and using the 
median S-25OHD value for each category. P < 0.05 was 
considered to be statistically significant. All reported 
P-values are two-sided.
Results
The characteristics of the study participants are presented 
in Table 1, both for the whole cohort and for subgroups 
of women with and without a later GDM diagnosis. 
Maternal age was 25–34 years for 66% of cases, and the 
median (IQR) pre-pregnancy BMI was 24.4 (6.3) kg/m2. 
Approximately 93% of participants were married or lived 
with a partner. Women who later developed GDM were 
more likely to be primi/multiparous and had higher 
pre-pregnancy BMI [median (IQR) 26.6 (8.8) kg/m2 vs. 
24.2 (5.9) kg/m2] but lower gestational weight gain [mean 
(SD) 9.7 (6.1) kg vs. 12.7 (5.2) kg] than those who did not 
develop GDM. No association was found between the vi-
tamin D status and BMI or social status, other than mar-
ital status. Single mothers tended to have lower S-25OHD 
concentrations than married or partnered mothers (P < 
0.05).
Table 2 shows the vitamin D status of the whole cohort, 
as well as the use of vitamin D supplements. The propor-
tion of women with S-25OHD concentrations ≥ 50 nmol/L 
(adequate) was 70%, whereas 25% of them had S-25OHD 
concentrations of 30–49.9 nmol/L (insufficient) and 5% 
had concentrations < 30 nmol/L (deficient). The majority 
of women (n = 766, 82%) who consumed supplements of 
vitamin D daily had a mean ± SD S-25OHD concentra-
tion of 66 ± 24 nmol/L. Interestingly, approximately 24% 
of women who took vitamin D supplements daily were 
classified as having an insufficient vitamin D level (< 50 
nmol/L). Women who reported never using vitamin D 
supplements (n = 104, 11%) had a mean ± SD S-25OHD 
concentration of 45 ± 18 nmol/L. In this group, approx-
imately 66% of women were defined as having an insuffi-
cient S-25OHD concentration (< 50 nmol/L), including 
18% who were defined as deficient (< 30 nmol/L). Both 
non-users and irregular users of vitamin D supplements 
had significantly reduced S-25OHD concentrations com-
pared with those taking daily supplements containing 
vitamin D (P < 0.01). A majority of the women (89%) 
who had sufficient vitamin D status (≥ 50 nmol/L) used 
vitamin D supplements on a daily basis.
The amounts of vitamin D found in the most com-
monly used supplements available in Icelandic markets 
are shown in Supplementary file. The number (%) of sub-
jects taking various daily supplements containing vitamin 
D, their 25OHD concentrations, and the number (%) of 
subjects categorized as having deficient (< 30 nmol/L), in-
sufficient (< 50 nmol/L), and sufficient (≥ 50 nmol/L) vita-
min D status are also shown in the same Supplementary 
file. Relatively few women used vitamin D (1 µg/100 g) 
enriched milk daily (n = 100). A large majority of women 
who consumed vitamin D-enriched milk daily also con-
sumed daily supplements containing vitamin D (n = 81). 
The average frequency of oily fish consumption was < 
0.5 times per week. The consumption of neither vitamin 
D-enriched milk nor oily fish was associated with vitamin 
D status.
Medical records were obtained for 837 women, includ-
ing 126 women (15%), who were eventually diagnosed 
with GDM (Table 3). The mean ± SD S-25OHD concen-
tration of the GDM group was 60 ± 24 nmol/L, compared 
with 63 ± 24 nmol/L in the non-GDM group (P > 0.05). 
Approximately 35% of subjects with GDM and 30% of 
non-GDM subjects had S-25OHD concentrations < 50 
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nmol/L. A gradual decrease in the proportion of women 
diagnosed with GDM was found to occur with increasing 
S-25OHD concentrations, going from 17.8% in the group 
with S-25OHD concentrations < 30 nmol/L to 12.8% in 
the group with S-25OHD concentrations ≥ 75 nmol/L (P 
for trend = 0.17). After adjustment for covariates, as pre-
sented in Table 3, the association was somewhat strength-
ened but remained non-significant (P = 0.11). The OR 
Table 1. Characteristics of the subjects divided according to the diagnosis of gestational diabetes
Characteristics All (n = 938) GDM (n = 126) Non-GDM (n = 711) Pa
Maternal age (year), n (%) n % n % n % 0.06b
 18–24 144 15.3 14 11.1 114 16.0
 25–29 341 36.2 48 38.1 261 36.7
 30–34 281 29.8 33 26.2 218 30.7
 35–39 138 14.6 24 19.0 95 13.4
 40–45 27 2.9 7 5.6 19 2.7
Parity, n (%) 0.03b
 Nulliparous 411 43.6 51 40.5 316 44.4
 Primi/multiparous 524 55.6 73 57.9 394 55.4
Marital status, n (%) 0.76b
 Married/cohabitant 874 92.7 106 95.1 661 95.0
 Single 42 4.5 6 4.9 35 5.0
Smoking in pregnancy, n (%) 43 4.6 7 5.6 31 4.4 0.12b
Education level, n (%) 0.34b
 Less than elementary school 5 0.5 0 0.0 5 0.7
 Elementary school 104 11.0 16 12.9 73 10.3
 High school and technical school 273 29.0 38 30.6 208 29.3
 Bachelor’s degree 317 24.9 35 28.2 257 36.2
 Master’s or doctorate degree 235 24.9 35 28.2 167 23.5
Height (cm), mean ± SD 167.5 ± 7.4 168.1 ± 5.2 167.3 ± 7.8 0.34c
Pre-pregnancy weight (kg), mean ± SD 72.3 ± 15.7 79.2 ± 19.0 71.3 ± 15.0 <0.01d
Pre-pregnancy body mass index (BMI), median (IQR) 24.4 6.3 26.5 8.8 24.2 5.9 <0.01d
Pre-pregnancy BMI (groups), n (%) <0.01b
 <18.5 kg/m2 18 1.9 2 1.6 13 1.8
 18.5–24.99 kg/m2 498 52.9 50 41.0 388 55.0
 25–29.99 kg/m2 240 25.5 30 24.6 186 26.4
 ≥30 kg/m2 171 18.2 40 32.8 118 16.7
Gestational weight gain (kg), mean ± SD 12.3 ± 6.9 9.7 ± 6.1 12.7 ± 5.2 <0.01c
Gestational week at delivery, median (interquartile range) 39.7 3.3 39.6 2.3 39.9 2.7 0.76d
Family history of type 2 diabetes, n (%) 11 1.2 2 1.8 6 1.0 <0.01b
Missing data in the total group: maternal age n = 7; height n = 7; pre-pregnancy weight n = 11; pre-pregnancy BMI n = 11; pre-pregnancy BMI (groups) 
n = 11; parity n = 3; marital status n = 22; prenatal smoking n = 8; education level n = 4. Information on GDM diagnosis was available for 837 subjects.
aDifferences between GDM and non-GDM.
bChi-square test for differences among groups.
cT-test for differences among groups.
dMann-Whitney U test for difference among groups.
Table 2. S-25OHD concentration (nmol/L) in all subjects (n = 938) and according to the use of supplements containing vitamin D (n = 935)
  n mean ± SD <30 nmol/L 30–49.9 nmol/L 50–74.9 nmol/L ≥ 75 nmol/L
n % n % n % n %
All subjects 938 63.0 ± 24.4 51 5.4 234 24.9 398 42.4 255 27.2
Not taking any supplements containing vitamin D 104 44.6 ± 17.5 19 18.3 50 48.1 29 27.9 6 5.8
Irregular use of supplements containing vitamin D* 65 55.1 ± 21.1 6 9.2 24 36.9 25 38.5 10 15.4
Daily vitamin D supplementation 766 65.9 ± 24.1 26 3.4 160 20.9 342 44.6 238 31.1
*Subjects reporting use of vitamin D supplements from 1–2 times per month up to 4–6 times per week.
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for GDM among women with S-25OHD concentrations 
≥ 75 nmol/L compared with those with S-25OHD concen-
trations < 30 nmol/L was 0.60 (95%CI: 0.25, 1.45).
Discussion
In this study, 70% of  the women (n = 942) had S-25OHD 
concentrations ≥ 50 nmol/L, which is considered ad-
equate. The remaining 30% had insufficient S-25OHD 
concentrations, with 25% presenting S-25OHD concen-
trations between 30 and 49.9 nmol/L (insufficient) and 
5% presenting S-25OHD concentrations < 30  nmol/L 
(deficient). Approximately 27% of  the women had 
S-25OHD concentrations ≥ 75 nmol/L. No clear asso-
ciation was observed between the vitamin D status and 
GDM in this study.
A majority of subjects in this study (approximately 
82%) used supplements containing vitamin D daily, in line 
with guidelines established by Icelandic health authorities 
(18). The frequency of vitamin D supplement intake in 
Iceland appears to be higher in this study than has been 
reported in other countries (19). The most common type 
of vitamin D supplements used in this study included 
 vitamin D tablets (51%), whereas fewer than 20% of par-
ticipants reported using the traditional Icelandic source 
of vitamin D, cod liver oil. A concerning finding was that 
25% of those who claimed they used supplements daily 
had inadequate vitamin D status. Some but not all of 
these participants reported the use of multivitamin sup-
plements, which typically contain 5–10 µg (200–400 IU) 
vitamin D in a daily dose. This dose is lower than the 
current 15 µg/day (600 IU) recommended daily intake 
(RDI) for adults, including pregnant women, established 
by Icelandic health authorities (18). In comparison, most 
single-nutrient vitamin D supplements available on the 
Icelandic market contain 25–50  µg (1,000–2,000 IU) 
 vitamin D per daily serving. Some women may have only 
recently begun to take supplements containing vitamin 
D, and may have entered pregnancy with low S-25OHD 
concentrations. The RDI for vitamin D is the required 
amount necessary to maintain an adequate vitamin D 
status, and may not be high enough to correct an insuffi-
cient status (20, 21). Van Groningen et al. (22) developed 
a practical method for calculating the vitamin D dose re-
quired to rapidly correct vitamin D deficiency in individu-
als using the following equation to estimate the necessary 
loading dose to increase vitamin D levels to 50 nmol/L: 
dose (IU) = 40 × [50 − serum 25-OHD (nmol/L)] × [body 
weight (kg)]. According to this equation, a 72-kg woman 
with a pre-pregnancy S-25OHD concentration of 24 
 nmol/L would require 6 months to achieve an S-25OHD 
concentration of 50 nmol/L when consuming 10 µg vita-
min D daily, which is the amount of vitamin D provided 
in many of the most commonly used multivitamins on the 
Icelandic market. If  the goal is to achieve an S-25OHD 
concentration > 50 nmol/L before week 20, the dose would 
need to be increased to as high as 45 µg/day (1,800 IU). In 
a recent study, a dose of 30 µg/day (1,200 IU) was sug-
gested to be necessary to maintain a sufficient vitamin D 
status (50 nmol/L) for the majority of pregnant, white-
skinned women at northern latitudes, which would also 
maintain an umbilical cord S-25OHD concentration of 
≥ 25–30 nmol/L for almost all newborns (23). Other stud-
ies have suggested that doses greater than the current RDI 
dose are necessary to maintain adequate vitamin D levels 
in pregnancy (24–26).
Previous studies conducted to examine the associa-
tion between the vitamin D status and GDM risk have 
reported somewhat conflicting results. Recent systematic 
reviews and meta-analyses found a relationship between 
low vitamin D status (insufficient or deficient) and an in-
creased risk of GDM (11–13, 27–29). These studies also 
reported that vitamin D levels were lower in women with 
GDM than in those with normal glucose levels. However, 
in this study, no significant difference in vitamin D status 
was observed between women who developed GDM later 
in pregnancy and those who did not, and no significant 
relationship was identified between low vitamin D levels 
and an increased risk of GDM. The proportion of women 
with vitamin D deficiency (S-25OHD < 30  nmol/L) was 
relatively low in our cohort, and the number of women 
taking supplements containing vitamin D may have 
been higher than in previous studies (these data are not 
always reported). Clinical trials examining the effect of 
vitamin  D supplements on GDM patients have yielded 
Table 3. Vitamin D status in subjects who later were diagnosed with gestational diabetes mellitus (n = 126) or not (total number of subjects 
included in the analysis n = 837)
Serum 25OHD (nmol/L) P for trenda
<30 30–49.9 50–74.9 ≥75
No cases (%)/n 8 (17.8%)/45 36 (17.2%)/209 53 (14.9%)/356 29 (12.8%)/227
Unadjusted OR (95% CI) 1.00 0.96 (0.41, 2.24) 0.81 (0.36, 1.83) 0.68 (0.29, 1.60) 0.17
Adjusted OR (95% CI)b 1.00 0.90 (0.38, 2.12) 0.77 (0.33, 1.76) 0.60 (0.25, 1.45) 0.11
aChi-square test.
bAdjusted for maternal age, parity and maternal pre-pregnancy body mass index, and smoking during pregnancy.
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unclear results (30). Researchers have identified several 
possible factors that might confound results. For example, 
low vitamin D concentrations might not be a contribut-
ing factor for GDM, or a causal relationship may exist 
in the opposite direction. In addition, factors associated 
with study design and whether the subjects were at high 
risk of developing GDM or vitamin D deficiency at base-
line could also affect the outcomes. The supplementation 
doses, supplementation periods, and methods used to 
assess S-25OHD concentrations can vary, and measure-
ments may be performed at different pregnancy stages. 
In some studies, all participants were supplemented with 
vitamin D for ethical reasons, which could also affect the 
results (24, 31, 32).
The primary strengths of this study are the inclusion 
of a large sample size and a high participation rate. Ac-
cording to Statistics Iceland, 2,188 infants were born in 
Iceland between April 2018 and September 2018 (which 
corresponds with the expected delivery dates for women 
attending 11–14-week ultrasound examinations during 
the study period). This study, therefore, includes 45% of 
the total population of pregnant women in Iceland. One 
of the limitations may be that recruitment was limited to 
the capital of Reykjavik. According to Statistics Iceland, 
approximately 70% of women in Iceland live in the capital 
region. However, we cannot exclude the possibility that 
the vitamin D status of women living outside the capital 
area may be different from that of the women included in 
this study. Furthermore, the number of women that were 
excluded for not speaking Icelandic indicates the impor-
tance of including English versions of the questionnaires 
for future studies performed in Iceland. The vitamin 
D status of pregnant women in Iceland has never been 
studied before; therefore, this study provides new and im-
portant information regarding the vitamin D status of 
this sensitive group during the winter months when skin-
based vitamin D production is limited in Iceland due to 
limited sunlight. 
This study also features some limitations. Although 
we obtained the estimated vitamin D levels from var-
ious types of  supplements available on the Icelandic 
market, additional details would be preferable, includ-
ing the total vitamin D intake from food. However, the 
results of  this study suggested that the contributions 
of  dietary vitamin D sources to total vitamin D intake 
and status are minimal. Although the Roche method 
used to analyze serum 25OHD concentration in this 
study has been successfully applied over the years, a re-
cent issue was identified that Roche has not yet been 
able to solve, in which the method occasionally falsely 
reports high measurements (33). Because of  this issue, 
vitamin D results are particularly closely monitored, 
and all samples that report high levels are repeated for 
confirmation.
Conclusion
Vitamin D supplementation is encouraged by Icelandic 
authorities and was widely used (approximately 80%) 
in the studied population. However, approximately one-
third of our cohort had serum S-25OHD concentrations 
below adequate levels (< 50 nmol/L) during the first tri-
mester of pregnancy, which suggests the necessary actions 
to increase vitamin D levels to be taken among this pop-
ulation. No clear association was observed between the 
vitamin D status and GDM in this study.
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